Acetate utilization promotes hormone therapy resistance in prostate cancer through neuroendocrine differentiation
Our findings uncovered the critical role of acetate metabolism in NED-mediated CRPC and suggest that ACSS2 inhibitors may represent a novel, low-toxicity strategy when combined with hormone therapy for treating patients with NED-mediated CRPC.
Authors
- Hailiang Hu (ORCID: https://orcid.org/0000-0001-9205-1603)
- Zhong Wang (ORCID: https://orcid.org/0000-0001-9787-7332)
- Yi Sun (ORCID: https://orcid.org/0000-0002-5841-4287)
- Bin Xu (ORCID: https://orcid.org/0000-0001-5511-8055)
- Lingfan Xu (ORCID: https://orcid.org/0000-0003-2465-241X)
- Huan Xu (ORCID: https://orcid.org/0000-0001-8721-6135)
- Dajun Gao
- Yanting Shen (ORCID: https://orcid.org/0000-0001-8129-0844)
Institutions
- Second Military Medical University (CN)
- Anhui Medical University (CN)
- Southern University of Science and Technology (CN)
- Shanghai Ninth People's Hospital (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Shanghai Pudong New Area Gongli Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Drug Resistance Updates
- Published
- 2024-10-06
- DOI
- https://doi.org/10.1016/j.drup.2024.101158
- Citations
- 14
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 5.87
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China